GleamWall
中文EN

FBIO Fortress Biotech, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1429260 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.3%
TTM net income YoY2,411.2%
TTM EPS YoY2,016.7%
Revenue 3-yr CAGR-4.7%
Net income 3-yr CAGR—

Margins

Gross margin66.2%
Operating margin-42.5%
Net margin143.0%
FCF margin—
EBITDA margin-41.9%

Returns

ROE92.8%
ROA43.4%
ROIC (approx.)-227.3%
Asset turnover0.30x

Leverage & solvency

Liabilities / assets36.8%
Debt / equity0.00x
Current ratio2.93x
Interest coverage-3.17x

Cash quality & payout

Operating cash flow / net income1.26x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19.16M$18.72M$16.04M$16.08M$17.63M$16.41M$13.14M$15.12M
Cost of revenue$5.88M$6.14M$6.22M$5.44M$5.75M$4.94M$4.79M$2.24M
Gross profit$13.28M$12.57M$9.82M$10.64M$11.88M$11.47M$8.35M$12.88M
R&D expense$1.68M$805,000$540,000-$367,000$208,000$8.13M$3.94M$9.69M
SG&A expense$17.82M$20.81M$15.89M$14.73M$17.41M$38.76M$25.66M$26.86M
Operating income-$7.19M-$10.01M-$7.74M-$4.79M-$6.81M-$36.47M-$22.32M-$23.84M
Interest expense$2.50M$1.48M$3.37M$2.04M$2.74M$2.52M$2.81M$2.59M
Pretax income-$8.31M$922,000$142.29M-$6.21M$8.85M-$11.65M-$24.69M-$25.98M
Income tax-$56,000$320,000$5.13M-$816,000$26,000$0$0$336,000
Net income-$5.84M-$468,000$110.37M-$3.94M$5.85M$15.49M-$10.58M-$6.76M
EBITDA-$7.09M-$9.91M-$7.65M-$4.70M-$6.71M-$36.37M-$22.19M-$23.69M
EPS (basic)-0.23-0.083.44—0.130.50-0.48—
EPS (diluted)-0.23-0.082.82—0.110.45-0.48—
Weighted avg. shares (diluted)33.75M31.79M38.41M—33.10M29.82M26.45M—
Balance sheet
Cash & equivalents$152.19M$196.58M$255.84M$79.38M$86.22M$74.39M$91.34M$58.81M
Receivables$47.39M$36.25M$24.99M$29.78M$17.98M$15.64M$18.02M$10.23M
Inventory$7.77M$8.16M$9.29M$9.62M$11.82M$12.85M$12.50M$14.43M
Current assets$210.36M$245.51M$295.48M$123.84M$118.50M$110.40M$126.90M$90.37M
PP&E, net$2.32M$2.41M$2.43M$2.52M$2.61M$2.70M$2.80M$3.26M
Intangibles$24.54M$25.51M$26.48M$27.61M$28.67M$29.73M$30.80M$31.86M
Total assets$280.21M$316.71M$356.87M$185.55M$181.41M$159.90M$178.07M$144.22M
Current liabilities$71.76M$62.02M$103.39M$49.74M$54.07M$57.52M$73.67M$71.40M
Long-term debt—$35.00M$37.50M$54.49M$47.77M$50.03M$56.38M$57.96M
Total debt—$35.00M$37.50M$54.49M$47.77M$50.03M$56.38M$57.96M
Total liabilities$103.19M$110.63M$154.50M$123.36M$116.22M$122.51M$145.59M$145.87M
Shareholders' equity$160.00M$164.14M$162.21M$49.87M$55.86M$43.92M$22.25M$22.74M
Net debt—-$161.58M-$218.34M-$24.89M-$38.44M-$24.36M-$34.96M-$853,000
Shares outstanding33.49M33.31M33.19M31.36M31.01M29.75M29.55M27.91M
Cash flow statement
Operating cash flow-$6.20M-$59.28M$203.85M-$12.54M-$6.11M-$27.56M-$19.56M-$12.91M
Capital expenditure$7,000——————$0
Free cash flow-$6.20M——————-$12.91M
Investing cash flow-$7,000-$79,000$0$0$2.87M$6.09M$1.17M-$15.00M
Financing cash flow-$38.19M$91,000-$27.39M$5.71M$15.07M$4.52M$52.14M$25.81M
Depreciation & amortization$100,000$100,000$93,000$92,000$100,000$100,000$126,000$144,000
Stock-based compensation$2.15M$2.88M$1.76M$2.46M$3.20M$16.79M$6.29M$16.19M
Dividends paid——$0$166,000$166,000$166,000$166,000$166,000

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.